Drug Name: Sunlenca

Active Ingredient: lenacapavir

Indications: To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations

Approval Date: 12/22/2022

Company: Gilead Sciences, Inc

Learn more:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215973s000lbl.pdf

Leave a Reply

Your email address will not be published. Required fields are marked *